| Date | Title | Description |
| 23.07.2024 | Stayble Therapeutics appoints new CFO | Stayble Therapeutics appoints new CFO
Tue, Jul 23, 2024 13:00 CET Report this content
Stayble Therapeutics AB announces that Erik Kullgren has been appointed as the new CFO, effective August 1, 2024.
Erik Kullgren has an MBA from the School... |
| 29.03.2023 | Startup Showcase: Alzinova AB – Pioneering Alzheimer’s Disease Drug Discovery Research | Alzinova AB is a Swedish biotechnology company engaged in drug discovery research for Alzheimer’s disease. The company’s proprietary AβCC peptide™ technology provides long-term R&D capabilities towards the discovery and development of n... |
| 01.11.2022 | Alzinova AB interim report January – September 2022 | Alzinova AB interim report January – September 2022
Tue, Nov 01, 2022 08:01 CET Report this content
The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - September 2... |
| 07.09.2022 | Alzinova announces new positive safety review of its Phase 1b study in Alzheimer’s disease | Alzinova announces new positive safety review of its Phase 1b study in Alzheimer’s disease
Wed, Sep 07, 2022 08:01 CET Report this content
Alzinova AB (publ) (“Alzinova” or “the Company”), announces today that a second external safety revie... |
| 25.08.2022 | Alzinova AB interim report January – June 2022 | Alzinova AB interim report January – June 2022
Thu, Aug 25, 2022 08:01 CET Report this content
The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - June 2022
Three ... |
| 03.08.2022 | Alzinova has recruited half of the patients for the ongoing Phase 1b study of the vaccine candidate ALZ-101 | Alzinova has recruited half of the patients for the ongoing Phase 1b study of the vaccine candidate ALZ-101
Wed, Aug 03, 2022 08:01 CET Report this content
Alzinova AB (publ) (”Alzinova” or “the Company”), announces today that the Phase 1b ... |
| 05.07.2022 | Alzinova establishes scaled-up manufacturing process for ALZ-101 ahead of Phase 2 | Alzinova establishes scaled-up manufacturing process for ALZ-101 ahead of Phase 2
Tue, Jul 05, 2022 08:01 CET Report this content
Alzinova AB (publ) (“Alzinova” or “the Company”) announces today that the Company has successfully verified th... |
| 01.07.2022 | Conversion of BTU into shares and warrants of series TO3 | Conversion of BTU into shares and warrants of series TO3
Fri, Jul 01, 2022 12:33 CET Report this content
The rights issue of units announced on 19 April 2022 (the “Rights Issue”) in Alzinova AB (publ) (“Alzinova” or the “Company”) has now b... |
| 15.06.2022 | Alzinova announces outcome of rights issue | Alzinova announces outcome of rights issue
Wed, Jun 15, 2022 08:01 CET Report this content
Alzinova AB (publ) (“Alzinova” or the “Company”) has completed the rights issue of units, consisting of shares and warrants of series TO3, which was ... |
| 08.06.2022 | Alzinova appoints Mangold Fondkommission as new liquidity provider | Alzinova appoints Mangold Fondkommission as new liquidity provider
Wed, Jun 08, 2022 08:01 CET Report this content
Alzinova AB (”Alzinova” or the ”Company”) has appointed Mangold Fondkommission AB (”Mangold”) as liquidity provider for the C... |
| 30.05.2022 | The subscription period in Alzinova’s rights issue starts today | The subscription period in Alzinova’s rights issue starts today
Mon, May 30, 2022 08:01 CET Report this content
Today, on 30 May 2022, the subscription period begins for Alzinova AB’s (publ) (“Alzinova” or the “Company”) rights issue of uni... |
| 24.05.2022 | Alzinova publishes prospectus in connection with rights issue of units | Alzinova publishes prospectus in connection with rights issue of units
Tue, May 24, 2022 10:11 CET Report this content
Alzinova AB (publ) (“Alzinova” or the “Company”) has prepared an EU growth prospectus (the “Prospectus”) in connection wi... |
| 24.05.2022 | Alzinova initiates development of a stable cell line to prepare the monoclonal antibody ALZ-201 for Alzheimer’s clinical trials | Alzinova initiates development of a stable cell line to prepare the monoclonal antibody ALZ-201 for Alzheimer’s clinical trials
Tue, May 24, 2022 15:32 CET Report this content
Alzinova AB (publ) (“Alzinova” or the “Company”) today announces... |
| 18.05.2022 | Bulletin from the annual general meeting of Alzinova AB (publ) | Bulletin from the annual general meeting of Alzinova AB (publ)
Wed, May 18, 2022 15:48 CET Report this content
The following resolutions were passed at the annual general meeting (the “AGM”) of Alzinova AB (publ) (“the Company”) on 18 May i... |
| 28.04.2022 | Alzinova announces positive safety review and continuation of its Phase 1b study in Alzheimer’s disease | Alzinova announces positive safety review and continuation of its Phase 1b study in Alzheimer’s disease
Thu, Apr 28, 2022 08:01 CET Report this content
Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing treatments for ... |
| 19.04.2022 | Alzinova AB interim report January – March 2022 | Alzinova AB interim report January – March 2022
Tue, Apr 19, 2022 07:46 CET Report this content
The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January - March 2022
Thre... |
| 19.04.2022 | The Board of Directors resolves on a rights issue of units of approximately SEK 42.5 million, part of the issue proceeds is intended to finance further development of ALZ-201 | The Board of Directors resolves on a rights issue of units of approximately SEK 42.5 million, part of the issue proceeds is intended to finance further development of ALZ-201
Tue, Apr 19, 2022 08:28 CET Report this content
The Board of Dire... |
| 19.04.2022 | Notice of annual general meeting in Alzinova AB (publ) | Notice of annual general meeting in Alzinova AB (publ)
Tue, Apr 19, 2022 08:36 CET Report this content
The shareholders of Alzinova AB (publ) reg. no. 556861-8168 (the “Company”) are hereby summoned to attend the Annual General Meeting (the... |
| 14.04.2022 | Alzinova publishes the Annual Report for 2021 | Alzinova publishes the Annual Report for 2021
Thu, Apr 14, 2022 07:46 CET Report this content
Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing disease-modifying treatments for Alzheimer’s, today announces that the Co... |
| 30.03.2022 | Alzinova improves manufacturing process of ALZ-101 to meet phase 2 requirements | Alzinova improves manufacturing process of ALZ-101 to meet phase 2 requirements
Wed, Mar 30, 2022 08:01 CET Report this content
Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing disease-modifying treatments for Alzhei... |
| 24.02.2022 | Alzinova AB Year end report 2021 | Alzinova AB Year end report 2021
Thu, Feb 24, 2022 08:01 CET Report this content
The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the year end report for the period January - December 2021
Twelve months, ... |
| 10.02.2022 | Alzinova receives approximately SEK 2,8 million through the exercise of the warrants of series TO2 2020/2022 | Alzinova receives approximately SEK 2,8 million through the exercise of the warrants of series TO2 2020/2022
Thu, Feb 10, 2022 08:01 CET Report this content
In October 2020, Alzinova AB (publ) (“Alzinova” or the “Company”) carried out an is... |
| 03.02.2022 | Today is the last day of trading in Alzinova's warrants of series TO2 2020/2022 | Today is the last day of trading in Alzinova's warrants of series TO2 2020/2022
Thu, Feb 03, 2022 08:01 CET Report this content
Today, 3 February 2022, is the last day of trading for the warrants of series TO2 2020/2022 (the “warrants”) whi... |
| 26.01.2022 | Alzinova announces that Mangold Insight initiates equity research coverage of the company | Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing treatments of Alzheimer's disease by specifically targeting neurotoxic amyloid-beta oligomers, today announces that Mangold Insight has been engaged by Alzinova to pro... |
| 26.01.2022 | Alzinova announces that Mangold Insight initiates equity research coverage of the company | Alzinova announces that Mangold Insight initiates equity research coverage of the company Wed, Jan 26, 2022 08:16 CET
Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing treatments of Alzheimer’s disease by specifically... |
| 24.01.2022 | The exercise period for Alzinova's warrants of series TO2 2020/2022 begins today | The exercise period for Alzinova's warrants of series TO2 2020/2022 begins today Mon, Jan 24, 2022 08:01 CET
In October 2020, Alzinova AB (publ) (“Alzinova” or the “Company”) carried out an issue of units with pre-emption rights for the sha... |
| 20.01.2022 | Alzinova completes humanisation work and selects lead candidate for monoclonal antibody ALZ-201 | Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company, today announces the company has successfully completed the humanisation work and selected a humanised lead candidate of its monoclonal antibody ALZ-201.
Alzinova initiated work ... |
| 20.01.2022 | Alzinova completes humanisation work and selects lead candidate for monoclonal antibody ALZ-201 | Alzinova completes humanisation work and selects lead candidate for monoclonal antibody ALZ-201 Thu, Jan 20, 2022 16:51 CET
Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company, today announces the company has successfully complete... |
| 15.12.2021 | Preclinical data confirm the unique specificity and disease-modifying potential of Alzinova’s monoclonal antibody, ALZ-201 | Preclinical data confirm the unique specificity and disease-modifying potential of Alzinova’s monoclonal antibody, ALZ-201 Wed, Dec 15, 2021 08:01 CET
Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing treatments of Al... |
| 15.12.2021 | Preclinical data confirm the unique specificity and disease-modifying potential of Alzinova's monoclonal antibody, ALZ-201 | Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing treatments of Alzheimer's disease by specifically targeting neurotoxic amyloid-β (Aβ) oligomers, today announces that a research project evaluating Alzinova's monoclon... |
| 29.10.2021 | First patient recruited into Alzinova's phase 1b clinical study with the oligomer-specific ALZ-101 vaccine against Alzheimer's disease | Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing treatments of Alzheimer's disease by specifically targeting neurotoxic amyloid-beta oligomers, today announces that the first patient has been recruited into its phase... |
| 29.10.2021 | First patient recruited into Alzinova's phase 1b clinical study with the oligomer-specific ALZ-101 vaccine against Alzheimer's disease | STOCKHOLM, Oct. 29, 2021 /PRNewswire/ -- Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing treatments of Alzheimer's disease by specifically targeting neurotoxic amyloid-beta oligomers, today announces that the first ... |
| 29.10.2021 | First patient recruited into Alzinova’s phase 1b clinical study with the oligomer-specific ALZ-101 vaccine against Alzheimer’s disease | First patient recruited into Alzinova’s phase 1b clinical study with the oligomer-specific ALZ-101 vaccine against Alzheimer’s disease Fri, Oct 29, 2021 15:01 CET
Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing trea... |
| 28.10.2021 | Alzinova AB interim report January – September 2021 | Alzinova AB interim report January – September 2021 Thu, Oct 28, 2021 08:01 CET
The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January –September 2021.
Nine months, Jan... |
| 30.09.2021 | Alzinova receives approval to start the first clinical study with the oligomer-specific ALZ-101 vaccine in patients with Alzheimer’s disease | Alzinova receives approval to start the first clinical study with the oligomer-specific ALZ-101 vaccine in patients with Alzheimer’s disease Thu, Sep 30, 2021 14:06 CET
Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company specialis... |
| 30.09.2021 | Alzinova : receives approval to start the first clinical study with the oligomer-specific ALZ-101 vaccine in patients with Alzheimer's disease | STOCKHOLM, Sept. 30, 2021 /PRNewswire/ -- Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company specialising in the treatment of Alzheimer's disease by specifically targeting neurotoxic amyloid-beta oligomers, announced today that t... |
| 30.09.2021 | Alzinova : receives approval to start the first clinical study with the oligomer-specific ALZ-101 vaccine in patients with Alzheimer's disease | Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company specialising in the treatment of Alzheimer's disease by specifically targeting neurotoxic amyloid-beta oligomers, announced today that the company has received approval from the ... |
| 26.08.2021 | Alzinova AB : interim report January - June 2021 | The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January -June 2021.
Six months, January - June 2021 Net sales amounted to 0 SEK (0 SEK). Result after financial items amo... |
| 26.08.2021 | Alzinova AB interim report January – June 2021 | Alzinova AB interim report January – June 2021 Thu, Aug 26, 2021 08:01 CET
The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January –June 2021.
Six months, January – June... |
| 26.07.2021 | Alzinova presents preclinical data on Alzheimer disease candidates at the AAIC conference | Alzinova presents preclinical data on Alzheimer disease candidates at the AAIC conference Mon, Jul 26, 2021 15:01 CET
Alzinova AB (publ) (FN STO: ALZ), is today presenting data on the monoclonal antibody, ALZ-201, at the Alzheimer’s Associa... |
| 19.05.2021 | Alzinova AB interim report January – March 2021 | Alzinova AB interim report January – March 2021 Wed, May 19, 2021 08:01 CET
The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the first quarter 2021.
Three months, January - March 20... |
| 18.05.2021 | Bulletin from the annual general meeting of Alzinova AB (publ) | Bulletin from the annual general meeting of Alzinova AB (publ) Tue, May 18, 2021 14:19 CET
The following resolutions were passed at the annual general meeting (the “AGM”) of Alzinova AB (publ) (“the Company”) on 18 May 2021. Due to the covi... |
| 18.05.2021 | ALZINOVA AB
Alzinova : Bulletin from the annual general meeting of Alzinova AB (publ) | The following resolutions were passed at the annual general meeting (the "AGM") of Alzinova AB (publ) ("the Company") on 18 May 2021. Due to the covid-19 pandemic, the Company's annual general meeting was carried out thr... |
| 21.04.2021 | ALZINOVA AB
Alzinova : Status update regarding application to start clinical study with ALZ-101 | Alzinova announces today that the documentation required for the application to start the planned Phase 1b clinical study with the drug candidate ALZ-101 will be ready during June. As such, the first patient first dose (FPFD) will not be ad... |
| 29.10.2020 | Alzinova : AB interim report January - September 2020 | STOCKHOLM, Oct. 29, 2020 /PRNewswire/ -- The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the quarterly report for the period July-September 2020, and the accumulated report for the period January-Septemb... |
